HER2 Biomarkers
News and reporting on HER2 biomarkers.
Reveal Genomics' TNBCDX predicted response rates and risk of relapse for patients on anthracycline-free neoadjuvant therapy in a retrospective validation study.
Concr Exploring Biomarkers of Response to Neoadjuvant TNBC Therapy
The firm will use its AI-based platform to create "digital twins" of TNBC patients and predict neoadjuvant treatment response.
Reveal Genomics HER2DX Assay to Be Prospectively Evaluated in ECOG-ACRIN Trial
Researchers will analyze the ability of HER2DX scores to predict patient outcomes in the Phase II CompassHER2 pCR trial.
Reveal Genomics' HER2DX Clinical Validation Trial Underway in Europe
The trial will randomize 300 patients with newly diagnosed early-stage HER2-positive breast cancer to treatment based on Reveal's test or standard therapy.
BostonGene, Hokkaido University to Study Biomarkers of Response in HER2-Positive Breast Cancer
The collaborators aim to use BostonGene's algorithms and genomics tools to identify HER2-positive breast cancer patients likely to respond to certain therapies.
Jun 4, 2023
Oct 12, 2020
Jun 12, 2020